HERC2 (95% CI 0.061–1.444; P = 0.0332) expression was significantly higher in male GC patients, whereas TIGIT (95% CI -0.980–-0.028; P = 0.0383) decreased in GC patients who received targeted therapy (Figure 6(b)). This evidence concerns the gene HERC2 and gastric cancer.